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Abstract
Background: Australia’s Aboriginal and Torres Strait Islander women have poorer survival and twice the disease
burden from breast cancer compared to other Australian women. These disparities are influenced, but not fully
explained, by more diagnoses at later stages. Incorporating breast screening, hospital and out of hospital treatment
and cancer registry records into a person-linked data system can improve our understanding of breast cancer
outcomes. We focussed one such system on a population-based cohort of Aboriginal women in South Australia
diagnosed with breast cancer and a matched cohort of non-Aboriginal women with breast cancer. We quantify
Aboriginal and non-Aboriginal women’s contact with publicly funded screening mammograms; quantify exposure
to a selection of cancer treatment modalities; then assess the relationship between screening, treatment and the
subsequent risk of breast cancer death.
Methods: Breast cancers registered among Aboriginal women in South Australia in 1990–2010 (N = 77) were matched
with a random selection of non-Aboriginal women by birth and diagnostic year, then linked to screening records, and
treatment 2 months before and 13months after diagnosis. Competing risk regression summarised associations of
Aboriginality, breast screening, cancer stage and treatment with risk of breast cancer death.
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Results: Aboriginal women were less likely to have breast screening (OR = 0.37, 95%CIs 0.19–0.73); systemic therapies
(OR = 0.49, 95%CIs 0.24–0.97); and, surgical intervention (OR = 0.35, 95%CIs 0.15–0.83). Where surgery occurred,
mastectomy was more common among Aboriginal women (OR = 2.58, 1.22–5.46). Each of these factors influenced the
risk of cancer death, reported as sub-hazard ratios (SHR). Regional spread disease (SHR = 34.23 95%CIs 6.76–13.40) and
distant spread (SHR = 49.67 95%CIs 6.79–363.51) carried more risk than localised disease (Reference SHR = 1). Breast
screening reduced the risk (SHR = 0.07 95%CIs 0.01–0.83). So too did receipt of systemic therapy (SHR = 0.06 95%CIs 0.
01–0.41) and surgical treatments (SHR = 0.17 95%CIs 0.04–0.74). In the presence of adjustment for these factors,
Aboriginality did not further explain the risk of breast cancer death.
Conclusion: Under-exposure to screening and treatment of Aboriginal women with breast cancers in South Australia
contributed to excess cancer deaths. Improved access, utilisation and quality of effective treatments is needed to
improve survival after breast cancer diagnosis.
Keywords: Breast cancer, Cancer screening, Cancer treatment, Aboriginal, Indigenous, Survival
Background
Australia’s Aboriginal and Torres Strait Islander women
have poorer breast cancer survival [1] and twice the dis-
ease burden from breast cancer compared to other Aus-
tralian women [2]. These disparities in outcomes are
influenced, but not fully explained [3], by relatively more
diagnoses at later tumour stages [4].
Early detection of breast cancers using mammographic
screening can improve survival outcomes [5–8] but dispar-
ities in participation are evidenced internationally on the
basis of ethnicity [9] and Indigeneity, for example among
Maori women in New Zealand [5, 10]. After breast cancer
diagnosis, disparities in cancer treatment are also recorded
in the US, particularly between African American and His-
panic women compared to white Americans [9]. In New
Zealand too, chemo and radio therapies were less frequent
among Maori than other women [11, 12] as was surgical
treatment [13]. Further, when surgery occurred, Maori
women were more likely to have a mastectomy rather than
breast conserving surgery [14].
A review of Australian breast cancer screening and treat-
ment patterns concluded there was consistent evidence of
lower screening [15–17] and evidence of lower rates of hos-
pital treatment for breast cancers among Aboriginal and
Torres Strait Islander women [17]. Different rates of sur-
gery have been reported by state and territory jurisdictions
with Aboriginal and Torres Strait Islander women receiving
comparable treatment to non-Indigenous women in
Queensland [18] but significantly less surgical intervention
in New South Wales (NSW) [19]. A national analysis of
women participating in breast screening found, however,
that Aboriginal and Torres Strait Islander women were
more likely than other women to undergo mastectomy ra-
ther than breast conserving surgery [6, 16].
To improve understanding of Aboriginal South Aus-
tralians’ cancer outcomes, an advanced cancer data sys-
tem was developed incorporating person-linked registry,
hospital, Pharmaceutical Benefits Scheme and Medicare
Benefit Schedule records within a wider Cancer Data
and Aboriginal Disparities (CanDAD) project [20]. Can-
DAD has previously described the role of Aboriginality,
cancer stage at diagnosis and broad treatment modalities
in cancer outcomes for all cancer types collectively [3,
21]. Female breast screening service records [6, 16] were
also available and facilitated an additional step in quanti-
fying the clinical pathway for the subgroup of Aboriginal
women diagnosed with breast cancer [22]. This will as-
sist with developing an improved national understanding
of breast cancer outcomes. Within South Australia, it
will help identify any unmet capacity to benefit from in-
formed, tailored service responses.
In pursuing three goals our study focusses on a
population-based cohort of Aboriginal women in South
Australia diagnosed with breast cancer and a matched co-
hort of non-Aboriginal women. Firstly, we examine differ-
ences in aspects of Aboriginal and non-Aboriginal women’s
contact with BreastScreen South Australia (BSSA), the gov-
ernment agency providing screening mammograms, by
quantifying the exposure to screening through BSSA. We
then quantify disparate exposure to a selection of cancer
treatment modalities before assessing the relationship be-
tween Aboriginality and stage at diagnosis, screening, treat-
ment and the subsequent risk of death from breast cancer.
Methods
A retrospective cohort study involving Aboriginal
women in South Australia diagnosed with breast cancer
between 1990 and 2010 and a randomly selected cohort
of non-Aboriginal women with breast cancer, matched
by years of birth and diagnosis.
Study governance
CanDAD’s Aboriginal Community Reference Group gov-
ernance ensured alignment of the study protocol with
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the principles of the South Australian Aboriginal Health
Research Accord [23].
Study design and participants
A retrospective cohort of all breast cancer cases diag-
nosed among female, Aboriginal South Australians in
the period 1990 to 2010 (N = 77) matched one to one
with a random selection of breast cancer cases among
non-Aboriginal females by birth year and diagnosis year.
Data sources and measurements
De-identified breast cancer data were provided by the
South Australian Cancer Registry (SACR), a population-
based registry coding diagnoses according to the Inter-
national Classification of Diseases for Oncology [24] and
further linked to ICD-10 coded causes and dates of death.
Cancer stage at diagnosis was described using Surveillance,
Epidemiology, and End Results Program summary staging
[25] as: localised - confined to tissue of origin; regional - in-
vaded adjacent tissue or regional nodes; distant - spread to
distant lymph nodes or other organs; and unknown stage
where insufficient staging data were available. Distant and
unknown stages were previously shown to have similar risk
of cancer death in the cohorts [3] and were aggregated to
ensure adequate cell sizes in our reporting.
SACR also records postal area at diagnosis, each of
which is categorised by quintile of socio-economic dis-
advantage using the Australian Bureau of Statistics Cen-
sus 2011 Index of Relative Socio-economic Advantage
and Disadvantage (ISRAD) [26]. For this study, we fur-
ther collapsed quintiles into two groups: Most disadvan-
taged - Quintile 1; and, All others - Quintiles 2 to 4.
Aboriginal status was established after cross-referencing
SACR records with linked study datasets including
SA-NT Datalink’s master linkage file, public hospital in-
patient and clinical information systems data and death
records [20]. The latter three collections each incorporate
a person’s self-identification of Aboriginal status. We
adopted that approach to avoid including false positives
(classifying non-Aboriginal cases as Aboriginal) and bias-
ing survival differences towards the null. While some false
classification of Aboriginality may have persisted, we be-
lieve misclassification would have been rare and have little
effect on comparisons by Aboriginal status.
South Australian women participating in the BSSA
program from 1989 to 2010 were probabilistically linked
with SACR breast cancer diagnoses [22]. Cohort cases
were then classified as: not linked and therefore not
listed on BSSA records; listed on BSSA records but with
no screening history; and listed and screened by BSSA.
Three treatment modes were included: surgery, systemic
therapies and radiotherapy. Surgery was classified as exci-
sion or destruction according to Australian standard classi-
fications of procedure invasiveness [27] with two further
subcategories of: partial mastectomy (procedures 3150000
and 3151500) and simple/subcutaneous mastectomy
(31518xx, 31524xx). Person-linked hospitalisations across
the period 1 July 1991 to 30 June 2013 and two months be-
fore and 13months after the SACR recorded diagnosis
month were sourced from the Integrated South Australian
Activity Collection and Alice Springs Hospital in the
Northern Territory [20, 21]. Systemic cancer therapies of
antineoplastic and immune-modulating agents were
sourced from the same hospital records and Pharmaceut-
ical Benefits Scheme records dated from 1 July 2002. Radio-
therapy notifications were also obtained from: the SACR;
hospitalisations; and Medicare Benefit Schedule records
dating from 1988 onwards.
Outcomes
The primary outcome was survival time from cancer
diagnosis to death from breast cancer or right censoring
when the observation period ended on 31st December
2011, whichever occurred first.
Statistical analysis
All analyses were performed within the Secure Unified Re-
search Environment [28] using Stata 14 [29]. Bivariate as-
sociations between Aboriginality, socio-demographic (age
and area level disadvantage) and cancer related variables
were examined using conditional logistic regression and
cross-tabulations. In assessing the adequacy of each
stratum cell size we applied threshold rules [30] of five or
more in sensitive areas focussed on medical issues and
treatment and three or more on the less sensitive issue of
being listed/not listed within administrative contacts [31].
Associations within each BSSA classification and treat-
ment mode were cross-tabulated and Pearson’s Chi-
Square Test used to highlight cells contributing to signifi-
cant differences within strata (at p < 0.05). The adjusted
odds of receiving treatment types were assessed concur-
rently by Aboriginal status and localised/non-localised
stage at diagnosis using multilevel logistic regression ana-
lyses (Stata’s melogit) [32].
Multivariable analyses of the risk of breast cancer death
are reported using sub-hazard ratio (SHR) estimates which
accounted for competing risk from non-cancer mortality
using Fine and Gray’s [33] method and Stata’s stcrprep
with stcox. Baseline Model 1 included the main effects of
Aboriginal status as exposure variable and stage at diagno-
sis (categorised as: localised disease; cancers with regional
spread; and, those with advanced, distant spread or where
spread was not determined) as moderator. Models 2 and 3
added BSSA listing and screening respectively. Model 4
included surgery, consisting of procedures for excision or
destruction, and systemic therapy, involving antineoplastic
or immune-modulating therapies, as treatment modes
having significant influences on the risk of cancer death.
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Three surgical sub-categories of no, partial and simple/
complete mastectomy were added in Model 5. Each model’s
parsimony and fit to the cohort data were considered against
Akaike Information Criterion (AIC) statistics [34]. Each
Model’s adherence to the proportional hazards assumption
was assessed by referring to Schoenfeld residuals [35].
Results
The Aboriginal (N = 77) and non-Aboriginal breast cancer
cohorts were equivalent on matching variables of year of
birth and year of diagnosis. Table 1 shows Aboriginal
women with breast cancer were more likely to be living in
the most disadvantaged quintile (IRSAD Q1) with un-
adjusted OR = 8.15 (95%CI 3.84–17.31). They had a lower
likelihood of formal contact with BSSA and were less
likely again to have a breast screening history (OR = 0.52,
95%CIs 0.26–1.03 and OR = 0.37, 95%CIs 0.19–0.73 re-
spectively). Aboriginal women were less likely to have re-
cords of hospitalisation for breast cancer and treatment by
systemic therapies (OR = 0.49, 95%CIs 0.24–0.97). Surgical
intervention was comparatively less frequent among Abo-
riginal women (OR = 0.35, 95%CIs 0.15–0.83) but more
likely to involve simple, total mastectomy when it did
occur (OR = 2.58, 95%CIs 1.22–5.46).
The cohort characteristics within selected BSSA classifi-
cations are summarised in Table 2. Aboriginal women aged
less than 50 years of age represented about one quarter of
cases (29%) but less than 10% of Aboriginal breast cancer
cases listed with BSSA compared to 19% of non-Aboriginal
cases. In particular, the age distribution of cohort members
not listed by BSSA features included comparatively more
and younger Aboriginal women than non-Aboriginal.
The characteristics of cohort cases receiving various
treatments (Table 3) were consistently distributed
across systemic therapies, surgery and radiotherapy
with the exception of comparatively less frequent sys-
temic therapy among localised breast cancers in Abo-
riginal women.
Table 1 Demographic distribution, tumour characteristics, comorbid conditions and cancer treatment types by Aboriginality
Aboriginal cohort Matched non-Aboriginal cohort
N % N % OR (unadjusted) 95% CIs
Total 77 100.0% 77 100.0%
Age
< 50 years 22 28.6% 20 26.0%
50–69 years 41 53.2% 41 53.2%
70+ years 14 18.2% 16 20.8%
2011 IRSAD Disadvantage
Most disadvantage Q1 48 62.3% 13 16.9% 8.15 3.84–17.31
Other Quintiles Q2 -Q4 29 37.7% 64 83.1% 1.00 Reference
Summary stage at diagnosis
Localised 36 46.8% 47 61.0% 1.00 Reference
Regional 24 31.2% 24 31.2% 1.31 0.64–2.66
Distant/Unknown 17 22.1% 6 7.8% 2.87 0.92–9.01
BreastScreen SA (BSSA) contact
Not listed with BSSA 31 40.3% 20 26.0% 1.00 Reference
Listed with BSSA, not screened 23 29.9% 16 20.8% 0.52 0.26–1.03
BSSA screened 23 29.9% 41 53.2% 0.37 0.19–0.73
Cancer treatmenta,b
Hospitalisation with cancer diagnosis 62 80.5% 71 92.2% 0.35 0.13–0.96
Systemic therapy 46 59.7% 58 75.3% 0.49 0.24–0.97
Surgeryc 56 72.7% 68 88.3% 0.35 0.15–0.83
Mastectomy
Partial 20 26.0% 38 49.4% 1.00 Reference
Simple 34 44.2% 25 32.5% 2.58 1.22–5.46
Radiotherapy 41 53.2% 51 66.2% 0.58 0.30–1.11
aUp to 2months before and 13 months after month of diagnosis
bCategories are not mutually exclusive
cSurgery includes a small number of excisions not categorised as mastectomy
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The simultaneous relationship between receipt of treat-
ment, stage at diagnosis and Aboriginality is summarised
in Table 4. Stage at diagnosis was not clearly predictive of
treatment received. However, Aboriginality was associated
with lower likelihood of hospitalisation with a principal
diagnosis of cancer (OR = 0.25, 95%CIs 0.07–0.09), receiv-
ing systemic therapy (OR = 0.19, 95%CIs 0.05–0.75) and
surgery (OR = 0.21, 95%CIs 0.06–0.75).
Tables 5 and 6 expresse the risk of breast cancer death
using sub-hazard ratios (SHR). Baseline Model 1 indicates
that Aboriginal women with breast cancer experienced a
comparatively greater risk of cancer death than non-Abori-
ginal cases (SHR= 5.13, 95%CIs 1.22–21.66) with regional
and distant/unknown staged disease at diagnosis also being
associated with markedly higher risk of cancer death than
localised disease (SHR= 14.21, 95%CIs 0.76–264.00 and
SHR = 13.74, 95%CIs 1.77–106.94 respectively). Model 2
did not find BSSA listing to be a statistically significant pro-
tective factor against risk of cancer death. In examining the
influence of completed BSSA screening however, Model 3
found a screening history with BSSA was associated with a
reduced risk of cancer death, SHR = 0.13 (95%CIs 0.03–
0.66). Further, the effect of stage at diagnosis remained but
Aboriginality no longer significantly affected the risk of can-
cer death and was removed. On adding treatment modal-
ities to Model 4, the effects of stage at diagnosis and breast
screening on risk of cancer death continued while both ex-
posure to systemic therapies (SHR = 0.06, 95%CIs 0.01–
0.41) and surgical treatment (SHR = 0.17, 95%CIs 0.04–
0.74) also showed independent associations with reduced
risk of cancer death. On further disaggregating surgery into
partial and simple mastectomy in Model 5, both showed an
association with reduced risk of cancer death. Models 4
and 5 were considered to best fit the cohort data on the
basis of their having the lowest AIC values observed. The
assumption of proportional hazards was upheld in each of
the models reported.
Discussion
This population-based study of Aboriginal and non-
Aboriginal women with breast cancer, matched by years
of birth and diagnosis, found that localised cancers were
Table 2 Characteristics of cohort cases listed and screened by BSSA
Table 3 Characteristics of cohort cases receiving treatment
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consistently associated with lower risk of death from
breast cancer compared to those with more advanced
spread at diagnosis. Our initial examination found this
was accompanied by a much greater risk of cancer death
among Aboriginal women compared to non-Aboriginal
women of equivalent age and year of diagnosis. However,
the level of risk associated with Aboriginality was miti-
gated by a history of breast screening through BSSA, a
marker of reduced risk of cancer death. This continued
to be the case in the presence of treatment with systemic
therapies and surgical intervention, each of which signifi-
cantly and independently reduced the risk of cancer death
further. While finding no evidence of differential treatment
effects by these factors for Aboriginal and non-Aboriginal
cases, we observed clear differences in exposure to risk re-
ducing factors. Specifically, there was a lack of contact with,
and screening by, BSSA among Aboriginal cases relative to
their matched, non-Aboriginal contemporaries. Moreover,
there was less exposure to cancer treatment. Where surgery
did take place, mastectomy rather than breast conserving
surgery was more than twice as likely among Aboriginal
women. In short, our results indicate that higher exposure
to more advanced disease at diagnosis and lower exposure
to breast screening and systemic/surgical treatments ex-
plained the higher risk of cancer death among similarly
aged women with breast cancer, not Aboriginality as such.
Our findings are consistent with the wider breast
screening literature that clearly indicates underutilisation
of breast screening among ethnic minorities and indi-
genous populations [5, 9, 10]. Most specifically within
the Australian context, the Australian Institute of Health
and Welfare [15] report around 33% of Aboriginal and
Torres Strait Islander and 53% of non-Indigenous
women in the relevant age ranges participate in breast
screening. Our results are closely aligned to this with
BSSA screening histories noted among 30 and 53% of
Aboriginal and non-Aboriginal cases respectively.
The reduced risk of cancer death after surgical and
systemic treatments is consistent with the parameters re-
ported within the NSW analysis of all female breast can-
cers [19]. Direct comparison of (sub) hazard ratios is not
possible because of the models derived but the estimated
effects of risk reduction from partial and simple mastec-
tomy are more readily compared. Our results align with
those of NSW where, after taking account of age, year of
diagnosis and stage at diagnosis, partial or localised sur-
gery was associated with greater risk reductions (SHR =
0.10 95%CIs 0.01–0.88 in SA and HR = 0.17 95%CIs
0.15–0.19 in NSW) than simple or complete mastectomy
(SHR = 0.23 95%CIs 0.06–0.88 in SA and HR = 0.31
95%CIs 0.28–0.34 in NSW).
The lower utilisation of treatment modes observed
among Aboriginal women compared to non-Aboriginal
women in our study is also generally consistent with
international studies from New Zealand [10, 14]. Simple
mastectomy was reported in approximately 45% of
Maori women and 34% of non-Maori with breast cancer
which aligns closely to the 44% among Aboriginal and
33% non-Aboriginal women in our study. Reports of
breast conserving surgery were also consistent among
non-Maori (52%) and non-Aboriginal women (49%).
Among Aboriginal women however, breast conserving
surgery was less common than observed among Maori
women (26% versus 44%). Our findings are also consist-
ent with those from NSW, another Australian jurisdic-
tion reporting variations in exposure to surgical
Table 4 Regression analysis relating treatment receipt,
Aboriginality and stage at diagnosis
OR (Adjusted) 95% CIs z p > |z|
Hospitalisation with cancer diagnosis
Aboriginal
No 1.00 Reference
Yes 0.25 0.07–0.90 −2.13 0.03
Stage at diagnosis
Localised 1.00
Regional 1.07 0.08–13.57 0.05 0.96




Yes 0.19 0.05–0.75 −2.37 0.02
Stage at diagnosis
Localised 1.00 Reference
Regional 5.42 0.86–34.06 1.80 0.07




Yes 0.21 0.06–0.75 −2.42 0.02
Stage at diagnosis
Localised 1.00
Regional 0.81 0.09–7.52 −0.18 0.85




Yes 0.56 0.27–1.17 −1.54 0.12
Stage at diagnosis
Localised 1.00 Reference
Regional 2.34 0.75–7.28 1.47 0.14
Distant/Unknown 0.99 0.24–4.01 −0.01 0.99
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treatments [19]. Among non-Aboriginal women with
breast cancer in NSW and South Australia, 49% received
breast conserving surgery while simple mastectomy was
performed in 39% of NSW and 33% of South Australian
cases. Fewer Aboriginal women with cancer had breast
conserving surgery in South Australia compared to
NSW (26% versus 37%) but the relative frequency of
mastectomy was similar at 44% and 48% respectively.
Mammography through BSSA is freely available to
women aged 40 to 74 years in Australia with active invi-
tation of those aged 50 to 69 during the study period.
Equivalent numbers of Aboriginal and non-Aboriginal
women in the latter age range were listed by BSSA, yet
fewer Aboriginal women participated in screening.
Women aged 40 to 49 years are free to initiate contact
with BSSA. Relatively few Aboriginal women with breast
cancer in this age range had done so, compared to over
half the non-Aboriginal women. The results suggest two
areas of response are warranted. The first is to continue
to innovate in delivering screening to all women, par-
ticularly to Aboriginal and Torres Strait Islander women,
with the aim of increasing uptake of BSSA invitations
and ensuring the screening experience is as favourable
as possible for Aboriginal and Torres Strait Islander
women [16, 36]. This will include careful consideration
of cultural appropriateness in screening activities [17, 37,
38]. The second may be to consider broadening active
invitation to include Aboriginal and Torres Strait Is-
lander women aged 40 to 49, since this group repre-
sented 25% of breast cancers detected in the cohort.
This would require discussion of the appropriateness
and effectiveness of mammography for women of these
ages and ethnicity [17]. For example, emerging evidence
of lower breast density among younger, Aboriginal
Table 5 Competing risk regression analysis for cancer survival among Aboriginal and matched non-Aboriginal cohorts, South
Australia 1990–2010
Model 1 - baseline Model 2 - BSSA listed Model 3 - BSSA screened
Subhazard Risk
Ratio
95% CIs z p > |z| Subhazard Risk
Ratio
95% CIs z p > |z| Subhazard Risk
Ratio
95% CIs z p > |z|
Aboriginal
No 1.00 Reference 1.00 Reference
Yes 5.13 1.22–
21.66




Local 1.00 Reference 1.00 Reference 1.00 Reference
Regional 14.21 0.76–
264.00
1.78 0.075 14.07 0.80–
246.18







2.50 0.012 13.79 1.67–
113.85





Yes 0.71 0.16–3.10 −0.46 0.647
Screened by BSSA
No 1.00 Reference












AIC 30.1 32.0 32.0
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women [1] and the potential for more aggressive breast
cancers in younger women generally [39], may suggest a
need to reconsider the sensitivity and specificity of
mammography among younger women. This will also
challenge current understandings of screening cost and
effectiveness and presents an opportunity to revise these
models toward equity weighted approaches [40]. None-
theless, the results suggest an unmet health need
whereby more than one-quarter of Aboriginal cases were
not actively offered a service specifically intended to re-
duce risk of cancer death.
Clear disparities in the uptake of cancer treatments were
also evident, despite Australia’s health care being univer-
sally available. In Australia, equity is a key performance
issue in health care delivery [41] and is assessed in terms
of timely access to services by special needs groups [42].
Our results provide evidence of inequitable access with
Aboriginal cases 65% less likely to be hospitalised with a
primary diagnosis of cancer within the observed period,
compared to matched, non-Aboriginal cases. Where
hospitalisation occurred, further inequities of utilisation
and quality [43, 44] emerged, with fewer Aboriginal
women with breast cancer treated with systemic therapies,
surgery or radiotherapy. There could be biological reasons,
dictated by the breast cancer subtypes among Aboriginal
women that influence differences in relevant systemic
treatments using hormonal tablets, chemotherapy and anti
HER2 targeted therapies for example. While valuable, that
line of analysis is outside the scope of our current study.
Our results make clear that the pervasiveness and extent
of observed differences in cancer interventions indicate
the need for effective, systematic responses to address
these gaps in service access, utilisation and quality. The
responses can be informed by systematically attending to
patient experiences [45] as a means of promoting im-
proved communication, cultural competency and collab-
oration among patients and clinicians. Additionally,
continued improvements to electronic patient care re-
cords can flag system inputs which are effective influences
on outputs and patient outcomes. For example, where
Table 6 Competing risk regression analysis for cancer survival among Aboriginal and matched non-Aboriginal cohorts, South
Australia 1990–2010
Model 4 - treated Model 5 - treated (with mastectomy)





Local 1.00 Reference 1.00 Reference
Regional 34.23 6.76–173.40 4.27 0.000 48.81 3.63–655.42 2.93 0.003





No 1.00 Reference 1.00 Reference
Yes 0.07 0.01–0.83 −2.11 0.035 0.05 0.01–0.40 −2.78 0.005
Systemic therapy
No 1.00 Reference 1.00 Reference
Yes 0.06 0.01–0.41 −2.88 0.004 0.05 0.01–0.21 −4.11 0.000
Surgical treatment
No 1.00 Reference
Yes 0.17 0.04–0.74 −2.36 0.018
Mastectomy
No mastectomy 1.00 Reference
Partial 0.10 0.01–0.88 −2.08 0.038
Simple/ subcutaneous 0.23 0.06–0.86 −2.19 0.029
AIC 28.9 28.9
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treatment pathways are initiated, documenting issues re-
lating to patient refusal and clinical contra-indications will
delineate obstacles to treatment uptake, where they oc-
curred in the care pathway, and who they involved.
As with previous studies in this subject area [18, 46],
we acknowledge our study was limited in its ability to
perfectly match on confounding variables included in
the initial design. For example, this resulted in the co-
hort of Aboriginal women being slightly younger on
average than their non-Aboriginal contemporaries, but
not to a statistically significant extent. Similarly, during
the study’s time frame, considerable changes in cancer
care practices took place. While differences in year of
diagnosis were limited to five-years, we acknowledge it
is possible that some residual confounding may have oc-
curred despite our adjusting for the matched variables.
Our analysis was strengthened by including a broad
range of data collections, using an efficient fixed effects
design and accounting for competing risk from non-can-
cer death. However, low case numbers limited our ability
to include ecological associations of geographic remote-
ness and the influence of comorbid conditions diagnosed
among individual cases. We also acknowledge the poten-
tial for lead-time effects, and possibly some over diagno-
sis, leading to an to overestimation of survival
improvement associated with breast screening as found
in the Australian BreastScreen service evaluations [47].
Nonetheless, our estimates of the risk of cancer death
are consistent with outcome studies in the international
and domestic literature using administrative hospital re-
cords. We also broadened the method used in other out-
come studies by including pharmaceutical benefits and
Medicare records. Additionally, the CanDAD project
successfully piloted the inclusion of breast screening re-
cords into a quantitative description of the aetiology of
Aboriginal women’s experience with breast cancer. In
doing so we began to explore the relationship between
cancer outcomes, screening behaviour and treatment ex-
posure, as a recognised major omission in our know-
ledge base in cancer control [8].
The study therefore enhances our understanding of
the risk of breast cancer death among Aboriginal South
Australians. Given the CanDAD project’s governance in-
cludes Aboriginal community representatives, South
Australian Cancer Services and colocation with the
South Australian Academic Health Science and Transla-
tion Centre, the knowledge developed is directly avail-
able for translation into benefits for Aboriginal and
Torres Strait Islander people through system-wide can-
cer control [48] and chronic disease [49] initiatives.
The results alert service planners to the lower levels of
screening and treatment of South Australian Aboriginal
women with breast cancers and its likely adverse effect
on cancer outcomes. This is important evidence for
introducing corrective initiatives aimed at earlier detec-
tion of cancers and the timely access and uptake of ef-
fective cancer treatments, while monitoring health
system change to maximise equitable outcomes.
While the findings demonstrate the value of using exist-
ing administrative records to assess exposure to, and the
outcomes from, components of cancer care from detec-
tion to treatment, the data do not inform on re-screening
or post-screening assessment [16], time to treatment,
whether treatment courses were completed, or the cura-
tive intent of interventions. Consequently, our study raises
two particular research and development opportunities.
The first is to better understand biological influences on
age at diagnosis and breast cancer subtypes among Abori-
ginal women and their subsequent influences on effective
treatment modalities. The second is to incorporate screen-
ing records for other conditions (bowel and cervix) [8],
broaden the screening data fields and further relevant clin-
ical information with the aim of informing continuous
quality improvement activities.
Conclusions
Our results demonstrate the risk of cancer death after
breast cancer diagnosis is significantly influenced by con-
trollable factors including: participation in mammographic
screening; early stage diagnosis; and treatment with sys-
temic therapies and surgery. Moreover, they demonstrate
Aboriginality does not need to be synonymous with poor
outcomes following breast cancer diagnosis. Rather, im-
proving exposure to effective interventions among Abori-
ginal and Torres Strait Islander breast cancer cases is
likely to result in improved, more equitable outcomes. En-
couraging targeted, earlier access to cancer care services
and maximising the utilisation and quality of effective, cul-
turally appropriate cancer interventions in early detection
and treatment should be actively promoted to reduce the
risk of death from breast cancer and improve survival after
breast cancer diagnosis in the Aboriginal and Torres Strait
Islander population.
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